Strive’s share price has fallen sharply in recent years, yet the stock still screens as undervalued on market multiples while its broader valuation checks remain weak. This leaves investors with a mixed message on what the current price really offers.

• Strive has declined about 90% over the past 3 years, which signals that the market has heavily reset expectations for the business.
• Any improvement in Strive’s ability to turn revenue into consistent cash flow can help support the current valuation, but ongoing concerns around execution and profitability remain a key risk to how the stock is priced.
• Strive passes only 2 of 6 valuation checks, which means that despite the multiple suggesting the stock is undervalued, the broader picture does not point to a clear bargain overall, according to these tests.

The issue now is whether Strive’s current price already reflects these risks, or if the apparent discount on some metrics still offers enough compensation for them.

Does Strive Look Undervalued on Book Value?

The price to book ratio suits Strive because the company is still working toward consistent cash flow, so its balance sheet is a useful anchor. Strive currently trades at about 1.3x P/B, compared with around 2.5x for the wider Medical Equipment industry and roughly 2.7x across close peers. That puts the stock at a sizeable discount to both groups on this metric.

This gap suggests the market is valuing Strive’s equity base more cautiously than the sector, likely reflecting ongoing questions around profitability and execution. For investors, the key question is whether that lower multiple is a fair reflection of these risks or if it offers additional potential if the business makes progress on turning its assets into steadier returns.

On the P/B multiple alone, Strive stock appears undervalued relative to its industry and peer group.

The Strive Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Strive pick up where this valuation puzzle leaves off by spelling out what would need to happen to Strive's revenue, margins and earnings for the stock to be worth materially more or less than today's price, based on scenarios shared on the Community page. Rather than relying on a single multiple or model output, each narrative lays out the assumptions behind its fair value so you can compare them with how the company actually performs over time.

You can add your voice to the Strive story by sharing a Narrative that sets out your number driven view on the future of its growth, margins and execution. Put your thesis on record and track how it compares with Strive's actual results over time.

Do you think there's more to the story for Strive? Head over to our Community to see what others are saying!

The Bottom Line

Strive screens as undervalued on market multiples, particularly on P/B, but the weak overall valuation checks temper that signal. The market appears to be pricing in meaningful uncertainty around profitability and execution, which is why the discount is not an automatic bargain. For you, the key question is whether Strive can turn its asset base into steadier earnings and cash flow, or whether the current discount simply reflects risks that have yet to be resolved.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.